NCT00944450View on ClinicalTrials.gov

Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

September 30, 2004

Study Completion Date

November 30, 2004

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin phosphate anhydrous formulation

Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.

DRUG

Comparator: sitagliptin phosphate monohydrate form

Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00944450 - Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027) | Biotech Hunter | Biotech Hunter